Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Sells $36,292.05 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $31.91 on Thursday. The business’s fifty day moving average is $37.27 and its 200 day moving average is $35.37. The company has a market capitalization of $1.76 billion, a PE ratio of 29.82 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after acquiring an additional 22,852 shares in the last quarter. Stephens Investment Management Group LLC boosted its position in shares of Supernus Pharmaceuticals by 1.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares during the period. Pacer Advisors Inc. increased its stake in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock valued at $54,633,000 after purchasing an additional 28,517 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock valued at $41,248,000 after buying an additional 95,777 shares in the last quarter.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.